UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049589
Receipt number R000056474
Scientific Title A Study to Evaluate Constant Load Exercise Performance After Ingestion of Test Food in Healthy University Students - A Randomized, Double-Blind, Placebo-Controlled Crossover Trial-
Date of disclosure of the study information 2022/11/23
Last modified on 2022/11/22 22:06:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study to Evaluate Constant Load Exercise Performance After Ingestion of Test Food in Healthy University Students
- A Randomized, Double-Blind, Placebo-Controlled Crossover Trial-

Acronym

A Study to Evaluate Constant Load Exercise Performance After Ingestion of Test Food
- A Randomized, Double-Blind, Placebo-Controlled Crossover Trial-

Scientific Title

A Study to Evaluate Constant Load Exercise Performance After Ingestion of Test Food in Healthy University Students
- A Randomized, Double-Blind, Placebo-Controlled Crossover Trial-

Scientific Title:Acronym

A Study to Evaluate Constant Load Exercise Performance After Ingestion of Test Food
- A Randomized, Double-Blind, Placebo-Controlled Crossover Trial-

Region

Japan


Condition

Condition

Healthy Male University Students

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the effects of a single dose of test food on the performance of constant-load exercise (five conditions with different exercise load conditions).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Oxygen uptake

Key secondary outcomes

Oxygen utilization efficiency, ventilation rate, carbon dioxide expiration rate, respiratory exchange ratio, respiratory rate, heart rate, Time to all out (100, 125% VO2max only), blood lactate concentration, blood active ingredient concentration, urinary active ingredient excretion, subjective exercise intensity


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

10

Purpose of intervention

Prevention

Type of intervention

Food Other

Interventions/Control_1

Exercise load (25%VO2max) and placebo
blood drawing

Interventions/Control_2

Exercise load (25%VO2max) and test food (active ingredient 10mg)
blood drawing

Interventions/Control_3

Exercise load (50%VO2max) and placebo
blood drawing

Interventions/Control_4

Exercise load (50%VO2max) and test food (active ingredient 10mg)
blood drawing

Interventions/Control_5

Exercise load (75%VO2max) and placebo
blood drawing

Interventions/Control_6

Exercise load (75%VO2max) and test food (active ingredient 10mg)
blood drawing

Interventions/Control_7

Exercise load (100%VO2max) and placebo
blood drawing

Interventions/Control_8

Exercise load (100%VO2max) and test food (active ingredient 10mg)
blood drawing

Interventions/Control_9

Exercise load (125%VO2max) and placebo
blood drawing

Interventions/Control_10

Exercise load (125%VO2max) and test food (active ingredient 10mg)
blood drawing


Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male

Key inclusion criteria

1)Healthy subjects who are aged 20-59
2)Subjects whose maximal oxygen consumption (VO2max) is 38 mL/kg min or greater
3)Subjects who can participate in dietary interventions, intake of test foods, blood samplings, urine samplings, and maintain rest as scheduled
4)Subjects who voluntarily give written informed consent

Key exclusion criteria

1)Subjects whose blood test results are judged to be ineligible for this study by lead principal investigator
2)Subjects with gastrointestinal, cardiovascular, endocrine, or other disorders, or with a history of such disorders, who are judged by lead principal investigator to be ineligible for the study
3)As a rule, subjects who regularly use drugs for the treatment of diseases
4)Subjects who consume health food products that affect the test
5)Subjects who may conduct doping tests
6)Subjects with allergies
7)Subjects who are judged to be ineligible for this study by lead principal investigator

Target sample size

16


Research contact person

Name of lead principal investigator

1st name Futoshi
Middle name
Last name Ogita

Organization

National Institute of Fitness and Sports in Kanoya

Division name

Department of Sports and Life Sciences

Zip code

891-2393

Address

1 Shiromizu-cho,Kanoya, Kagoshima

TEL

+81-994-46-4878

Email

ogita@nifs-k.ac.jp


Public contact

Name of contact person

1st name Yasutaka
Middle name
Last name Ikeda

Organization

Otsuka Pharmaceutical Co., Ltd.

Division name

Saga Nutraceuticals Research Institute

Zip code

842-0195

Address

5006-5 Yoshinogari-cho, Kanzaki-gun, Saga

TEL

+81-952-52-1522

Homepage URL


Email

Ikeda.Yasutaka@otsuka.jp


Sponsor or person

Institute

National Institute of Fitness and Sports in Kanoya

Institute

Department

Personal name



Funding Source

Organization

Otsuka Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Otsuka Pharmaceutical Co., Ltd.

Address

Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8242, Japan

Tel

+81-3-6717-1499

Email

shimizu_se@otsuka.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 11 Month 23 Day


Related information

URL releasing protocol

under submission

Publication of results

Unpublished


Result

URL related to results and publications

under submission

Number of participants that the trial has enrolled

16

Results

Test food significantly reduced VO2.

Results date posted

2022 Year 11 Month 22 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Healthy Volunteers

Participant flow

Subjects were selected based on the key inclusion and exclusion criteria.

Adverse events

ND

Outcome measures

Primary Outcomes:
Oxygen Uptake

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 03 Month 07 Day

Date of IRB

2018 Year 12 Month 25 Day

Anticipated trial start date

2019 Year 04 Month 20 Day

Last follow-up date

2020 Year 02 Month 12 Day

Date of closure to data entry

2020 Year 02 Month 12 Day

Date trial data considered complete

2020 Year 02 Month 12 Day

Date analysis concluded

2020 Year 10 Month 09 Day


Other

Other related information



Management information

Registered date

2022 Year 11 Month 22 Day

Last modified on

2022 Year 11 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056474